Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Endocrinol Diabetes Metab. 2023 Sep;6(5):e439. doi: 10.1002/edm2.439. Epub 2023 Jul 19.
Macro-algae products have been shown to ameliorate the metabolic disorders state. Thus, highlighting their function as supplementary therapeutic agents can be a novel strategy for clinical therapies. This systematic review and meta-analysis of clinical trials aimed to summarize the effect of macro-algae consumption on serum lipid profile, glycaemic control and anthropometric factors.
In this systematic review and meta-analysis, a comprehensive search was performed for relevant studies published up to May 2023. The Cochran's Q test and I-square (I ) tests were used to evaluate heterogeneity across the included studies. The meta-analysis was conducted using random-effects model (DerSimonian and Laird), and weighted mean difference (WMD) was considered as the pooled effect size.
Out of 8602 papers in the initial screening, eight clinical trials with a total of 438 participants were included into this meta-analysis. The results indicated that macro-algae supplementation significantly decreased serum levels of total cholesterol (TC) (WMD = -6.7 mg/dL; 95% CI: -12.59, -0.80; item = 0.026) and low-density lipoprotein cholesterol (LDL-c) (WMD = -8.25 mg/dL; 95% CI: -15.38, -1.12; p-value = .023). There was an increase in level of high-density lipoprotein cholesterol (HDL-c) (WMD = 0.48 mg/dL; 95% CI: -2.05, 3.01; p-value = .71) which was not statistically significant. Macro-algae supplementation reduced body mass index (BMI) (WMD = -0.28 kg/m ; 95% CI: -0.96, 0.41; p-value = .426), weight (WMD = -0.39 kg; 95% CI: -3.6, 2.83; p-value = .81), waist circumference (WC) (WMD = -0.52 cm; 95% CI: -2.71, 1.66; p-value = .64), fasting blood sugar (FBS) (WMD = -1.95 mg/dL; 95% CI: -5.19, 1.28; p-value = .24) and HbA1c (WMD = -0.02%; 95% CI: -0.14, 0.09; p-value = .66) in intervention group.
This meta-analysis indicated that macro-algae supplementation significantly decreased TC and LDL-c level. It can also increase HDL-c level and reduce anthropometric indices and glycaemic control factors.
藻类产品已被证明可以改善代谢紊乱状态。因此，强调其作为辅助治疗剂的功能可能是临床治疗的一种新策略。本系统评价和荟萃分析的临床试验旨在总结藻类消费对血清脂质谱、血糖控制和人体测量因素的影响。
在这项系统评价和荟萃分析中，我们对截至 2023 年 5 月发表的相关研究进行了全面搜索。我们使用 Cochran's Q 检验和 I 平方（I ）检验来评估纳入研究的异质性。荟萃分析采用随机效应模型（DerSimonian 和 Laird）进行，加权均数差（WMD）被视为汇总效应大小。
在最初的筛选中，有 8602 篇论文，其中有 8 项临床试验共 438 名参与者被纳入本荟萃分析。结果表明，藻类补充剂显著降低了总胆固醇（TC）（WMD=-6.7mg/dL；95%CI：-12.59，-0.80；I²=0.026）和低密度脂蛋白胆固醇（LDL-c）（WMD=-8.25mg/dL；95%CI：-15.38，-1.12；p 值=0.023）的血清水平。高密度脂蛋白胆固醇（HDL-c）水平升高（WMD=0.48mg/dL；95%CI：-2.05，3.01；p 值=0.71），但无统计学意义。藻类补充剂降低了体重指数（BMI）（WMD=-0.28kg/m²；95%CI：-0.96，0.41；p 值=0.426）、体重（WMD=-0.39kg；95%CI：-3.6，2.83；p 值=0.81）、腰围（WC）（WMD=-0.52cm；95%CI：-2.71，1.66；p 值=0.64）、空腹血糖（FBS）（WMD=-1.95mg/dL；95%CI：-5.19，1.28；p 值=0.24）和糖化血红蛋白（HbA1c）（WMD=-0.02%；95%CI：-0.14，0.09；p 值=0.66）。
这项荟萃分析表明，藻类补充剂显著降低了 TC 和 LDL-c 水平。它还可以提高 HDL-c 水平，降低人体测量指标和血糖控制因素。
